Press releases

Browse our latest press releases below, or visit our investor site directly for a complete list of all recent and archived press releases.

June 26, 2026

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

June 3, 2026

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 2, 2026

Lantheus’ LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

May 27, 2026

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

May 21, 2026

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

May 19, 2026

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 7, 2026

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

April 23, 2026

Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time

March 17, 2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

For access to press releases before 2022 and full-text search capabilities, please visit our investor site.

Contact

Media

Melissa Downs
Executive Director
External Communications

646-975-2533

media@lantheus.com

Investors

Mark Kinarney
Vice President
Investor Relations

978-671-8842

ir@lantheus.com